35
Through the Prevention and/or Management of Adverse Events in Multiple Myeloma

Optimizing Therapy Through the Prevention and/or Management of Adverse Events in Multiple Myeloma

  • Upload
    tausiq

  • View
    39

  • Download
    0

Embed Size (px)

DESCRIPTION

Optimizing Therapy Through the Prevention and/or Management of Adverse Events in Multiple Myeloma. Goal Statement. Case #1 . Question . Venous Thromboembolism. Risk Factors for VTE in Patients With Malignancy. VTE Incidence With Thalidomide or Lenalidomide Without Thromboprophylaxis. - PowerPoint PPT Presentation

Citation preview

Page 1: Optimizing Therapy Through the Prevention and/or Management of Adverse Events in Multiple Myeloma

Optimizing Therapy Through the Prevention and/or Management

of Adverse Events in Multiple Myeloma

Page 2: Optimizing Therapy Through the Prevention and/or Management of Adverse Events in Multiple Myeloma

Goal Statement

Page 3: Optimizing Therapy Through the Prevention and/or Management of Adverse Events in Multiple Myeloma

Case #1

Page 4: Optimizing Therapy Through the Prevention and/or Management of Adverse Events in Multiple Myeloma

Question

Page 5: Optimizing Therapy Through the Prevention and/or Management of Adverse Events in Multiple Myeloma

Venous Thromboembolism

Page 6: Optimizing Therapy Through the Prevention and/or Management of Adverse Events in Multiple Myeloma

Risk Factors for VTE in Patients With Malignancy

Page 7: Optimizing Therapy Through the Prevention and/or Management of Adverse Events in Multiple Myeloma

VTE Incidence With Thalidomide or Lenalidomide Without Thromboprophylaxis

Page 8: Optimizing Therapy Through the Prevention and/or Management of Adverse Events in Multiple Myeloma

Guideline Recommendations: Prevention of VTE

Page 9: Optimizing Therapy Through the Prevention and/or Management of Adverse Events in Multiple Myeloma

Guideline Recommendations: Prevention of VTE (cont)

Page 10: Optimizing Therapy Through the Prevention and/or Management of Adverse Events in Multiple Myeloma

Case #1 (cont)

Page 11: Optimizing Therapy Through the Prevention and/or Management of Adverse Events in Multiple Myeloma

Question

Page 12: Optimizing Therapy Through the Prevention and/or Management of Adverse Events in Multiple Myeloma

Bisphosphonate-Related ONJ

Page 13: Optimizing Therapy Through the Prevention and/or Management of Adverse Events in Multiple Myeloma

BRONJ Incidence

Page 14: Optimizing Therapy Through the Prevention and/or Management of Adverse Events in Multiple Myeloma

BRONJ Risk Factors

Page 15: Optimizing Therapy Through the Prevention and/or Management of Adverse Events in Multiple Myeloma

BRONJ Definition

Page 16: Optimizing Therapy Through the Prevention and/or Management of Adverse Events in Multiple Myeloma

Prevention of BRONJ

Page 17: Optimizing Therapy Through the Prevention and/or Management of Adverse Events in Multiple Myeloma

Strategies for Preventing BRONJ

Page 18: Optimizing Therapy Through the Prevention and/or Management of Adverse Events in Multiple Myeloma

Treatment of Patients With BRONJ

Page 19: Optimizing Therapy Through the Prevention and/or Management of Adverse Events in Multiple Myeloma

Case #2

Page 20: Optimizing Therapy Through the Prevention and/or Management of Adverse Events in Multiple Myeloma

Case #2 (cont)

Page 21: Optimizing Therapy Through the Prevention and/or Management of Adverse Events in Multiple Myeloma

Question

Page 22: Optimizing Therapy Through the Prevention and/or Management of Adverse Events in Multiple Myeloma

Peripheral Neuropathy

Page 23: Optimizing Therapy Through the Prevention and/or Management of Adverse Events in Multiple Myeloma

TiPN and BiPN

Page 24: Optimizing Therapy Through the Prevention and/or Management of Adverse Events in Multiple Myeloma

Carfilzomib: PN

Page 25: Optimizing Therapy Through the Prevention and/or Management of Adverse Events in Multiple Myeloma

Management of PN

Page 26: Optimizing Therapy Through the Prevention and/or Management of Adverse Events in Multiple Myeloma

Management of PN: TiPN

Page 27: Optimizing Therapy Through the Prevention and/or Management of Adverse Events in Multiple Myeloma

Management of PN: BiPN

Page 28: Optimizing Therapy Through the Prevention and/or Management of Adverse Events in Multiple Myeloma

Question

Page 29: Optimizing Therapy Through the Prevention and/or Management of Adverse Events in Multiple Myeloma

Myelosuppression

Page 30: Optimizing Therapy Through the Prevention and/or Management of Adverse Events in Multiple Myeloma

Myelosuppression: Bortezomib

Page 31: Optimizing Therapy Through the Prevention and/or Management of Adverse Events in Multiple Myeloma

Myelosuppression: Lenalidomide

Page 32: Optimizing Therapy Through the Prevention and/or Management of Adverse Events in Multiple Myeloma

Myelosuppression: Carfilzomib

Page 33: Optimizing Therapy Through the Prevention and/or Management of Adverse Events in Multiple Myeloma

Question & Answer Session

Page 34: Optimizing Therapy Through the Prevention and/or Management of Adverse Events in Multiple Myeloma
Page 35: Optimizing Therapy Through the Prevention and/or Management of Adverse Events in Multiple Myeloma